Eileen E. Parkes, Steven M. Walker, Laura E. Taggart, Nuala McCabe et al.
Background: Previously we identified a DNA damage response-deficient (DDRD) molecular subtype within breast cancer. A 44-gene assay identifying this subtype was validated as predicting benefit from DNA-damaging chemotherapy. This subtype was defined by interferon signaling. In this study, we address...